These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 15334243)

  • 81. The use of botulinum toxin in the treatment of adductor spasmodic dysphonia.
    Whurr R; Lorch M; Fontana H; Brookes G; Lees A; Marsden CD
    J Neurol Neurosurg Psychiatry; 1993 May; 56(5):526-30. PubMed ID: 8505645
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Botulinum toxin A and B: a comparative dosing study for spasmodic dysphonia.
    Blitzer A
    Otolaryngol Head Neck Surg; 2005 Dec; 133(6):836-8. PubMed ID: 16360499
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Treatment of adductor laryngeal breathing dystonia with botulinum toxin type A.
    Grillone GA; Blitzer A; Brin MF; Annino DJ; Saint-Hilaire MH
    Laryngoscope; 1994 Jan; 104(1 Pt 1):30-2. PubMed ID: 8295454
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Increased stability of airflow following botulinum toxin injection.
    Finnegan EM; Luschei ES; Gordon JD; Barkmeier JM; Hoffman HT
    Laryngoscope; 1999 Aug; 109(8):1300-6. PubMed ID: 10443837
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Botulinum toxin in the treatment of lingual movement disorders.
    Kasravi N; Jog MS
    Mov Disord; 2009 Nov; 24(15):2199-202. PubMed ID: 19795478
    [TBL] [Abstract][Full Text] [Related]  

  • 86. [Treatment of laryngeal dystonia with botulinum toxin].
    Olthoff A; Grosheva M; Reichel G; Volk GF; Laskawi R
    Fortschr Neurol Psychiatr; 2017 Aug; 85(8):450-462. PubMed ID: 28841743
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Abductor laryngeal dystonia: a series treated with botulinum toxin.
    Blitzer A; Brin MF; Stewart C; Aviv JE; Fahn S
    Laryngoscope; 1992 Feb; 102(2):163-7. PubMed ID: 1738288
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Treatment efficacy of electromyography versus fiberscopy-guided botulinum toxin injection in adductor spasmodic dysphonia patients: a prospective comparative study.
    Kim JW; Park JH; Park KN; Lee SW
    ScientificWorldJournal; 2014; 2014():327928. PubMed ID: 25383369
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Relationship of laryngeal botulinum toxin dosage to patient age, vitality, and socioeconomic issues.
    Young DL; Halstead LA
    J Voice; 2014 Sep; 28(5):614-7. PubMed ID: 24954039
    [TBL] [Abstract][Full Text] [Related]  

  • 90. The treatment of essential voice tremor with botulinum toxin A: a longitudinal case report.
    Warrick P; Dromey C; Irish J; Durkin L
    J Voice; 2000 Sep; 14(3):410-21. PubMed ID: 11021508
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Botulinum toxin in the treatment of recalcitrant mutational dysphonia.
    Woodson GE; Murry T
    J Voice; 1994 Dec; 8(4):347-51. PubMed ID: 7858670
    [TBL] [Abstract][Full Text] [Related]  

  • 92. [Neurolaryngology].
    Müller AH
    HNO; 2021 Sep; 69(9):734-741. PubMed ID: 34125237
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Major patterns of laryngeal electromyography and their clinical application.
    Yin SS; Qiu WW; Stucker FJ
    Laryngoscope; 1997 Jan; 107(1):126-36. PubMed ID: 9001277
    [TBL] [Abstract][Full Text] [Related]  

  • 94. [A probe into the relationship between spasmodic dysphonia and laryngeal paralysis].
    Yang S; He P; Lu S
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 1998 Dec; 33(6):328-30. PubMed ID: 11938840
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Essential palatal tremor treated with botulinum toxin.
    Carman KB; Ozkan S; Yarar C; Yakut A
    Pediatr Neurol; 2013 May; 48(5):415-7. PubMed ID: 23583064
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Refractory Dysphonia Due to Isolated Cricothyroid Muscle Dystonia.
    Kraft S; Childes J; Hillel A; Schindler J
    J Voice; 2016 Jul; 30(4):501-5. PubMed ID: 26239970
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Treatment of intractable tardive lingual dyskinesia with botulinum toxin.
    Beckmann YY; Seçil Y; Saka S; Kuserli A; Çiftçi Y
    J Clin Psychopharmacol; 2011 Apr; 31(2):250-1. PubMed ID: 21364341
    [No Abstract]   [Full Text] [Related]  

  • 98. Movement, visceral and autonomic disorders: use of botulinum toxin.
    Moore AP
    Hosp Med; 2003 Aug; 64(8):452-9. PubMed ID: 12958755
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Guidelines for the therapeutic use of botulinum toxin in movement disorders.
    Pagni CA
    Ital J Neurol Sci; 1998 Jun; 19(3):189-90. PubMed ID: 10933476
    [No Abstract]   [Full Text] [Related]  

  • 100. Botulinum toxin in motor disorders: practical considerations with emphasis on interventional neurophysiology.
    Traba López A; Esteban A
    Neurophysiol Clin; 2001 Aug; 31(4):220-9. PubMed ID: 11596529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.